1. Home
  2. SLNH vs MOLN Comparison

SLNH vs MOLN Comparison

Compare SLNH & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soluna Holdings Inc.

SLNH

Soluna Holdings Inc.

HOLD

Current Price

$1.30

Market Cap

174.8M

Sector

Technology

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.43

Market Cap

164.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLNH
MOLN
Founded
1961
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
174.8M
164.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SLNH
MOLN
Price
$1.30
$4.43
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$5.00
$3.75
AVG Volume (30 Days)
5.2M
4.3K
Earning Date
11-17-2025
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$28,782,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$45.98
$999.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$3.36
52 Week High
$5.14
$5.91

Technical Indicators

Market Signals
Indicator
SLNH
MOLN
Relative Strength Index (RSI) 38.93 54.75
Support Level $1.25 $4.16
Resistance Level $1.65 $4.44
Average True Range (ATR) 0.23 0.19
MACD 0.01 -0.01
Stochastic Oscillator 4.81 75.00

Price Performance

Historical Comparison
SLNH
MOLN

About SLNH Soluna Holdings Inc.

Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: